Forest Laboratories Inc. (FRX)
-NYSE 39.08 
1.57(4.19%) 02:51 SGT - Nasdaq Real Time Price
| Prev Close: | 37.51 |
|---|
| Open: | 38.01 |
|---|
| Bid: | 38.83 x 700 |
|---|
| Ask: | 38.84 x 2100 |
|---|
| 1y Target Est: | 38.29 |
|---|
| Beta: | 0.55 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 38.01 - 39.09 |
|---|
| 52wk Range: | 31.28 - 39.09 |
|---|
| Volume: | 2,677,188 |
|---|
| Avg Vol (3m): | 1,313,060 |
|---|
| Market Cap: | 10.41B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.12 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Forest Labs' longtime CEO Solomon to step down at year-endReuters(Thu, 23 May)
- Ironwood Pharma Prices Stock OfferingZacks(Thu, 23 May)
- Forest Labs CEO Howard Solomon to retireAP(Thu, 23 May)
- Forest Labs CEO Howard Solomon to retireAP(Thu, 23 May)
- Oakmark Fund Buys Forest Laboratories, DirecTV, UnitedHealth, Appleat Forbes(Thu, 23 May)
- Forest Laboratories Says Solomon to Leave CEO Postat Bloomberg(Thu, 23 May)
- Analyst downgrades Ironwood Pharma on expensesAP(Tue, 7 May)
- Icahn Enterprises 1Q net income surgesAP(Sat, 4 May)
- Ironwood Pharma skids following 1st-quarter reportAP(Wed, 24 Apr)
- Forest Labs fiscal 4Q profit plungesAP(Tue, 23 Apr)
Key Statistics
| Forward P/E (1 yr): | 24.90 |
|---|
| P/S (ttm): | 3.23 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Mar-14)
: | 0.88 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.11 |
|---|
| Mean Recommendation*: | 2.5 |
|---|
| PEG Ratio (5 yr expected): | 1.27 |
|---|
Business Summary
Forest Laboratories, Inc. develops, manufactures, and sells branded forms of ethical drug products primarily in the United States and Europe. It principally offers Namenda for the treatment of moderate and severe Alzheimer's disease; Bystolic...
View More